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Abstract 
Upregulation of selenium binding protein 1 (SELENBP1) mRNA expression has been reported in schizophrenia, primarily in the 
dorsolateral prefrontal cortex. However, peripheral blood studies are limited and results are inconsistent. In this study, we examined 
SELENBP1 mRNA expression in whole blood and protein expression in plasma from patients with recent-onset schizophrenia (n=30), 
treatment-resistant schizophrenia (n=71) and healthy controls (n=57). We also examined the effects of SELENBP1 genetic variation on 
gene and protein expression. We found lower SELENBP1 plasma protein level in patients with recent-onset schizophrenia (p=0.042) but 
not in treatment-resistant schizophrenia (p=0.81). Measurement of peripheral mRNA levels showed no difference between treatment-
resistant schizophrenia and healthy controls (p=0.234) but clozapine plasma levels (p=0.036) and duration of illness (p=0.028) were 
positively correlated with mRNA levels. Genetic variation was not associated with mRNA or protein expression. Our data represent the 
first peripheral proteomic study of SELENBP1 in schizophrenia and suggest that plasma SELENBP1 protein is downregulated in patients 
with recent-onset schizophrenia.  
Keywords: SELENBP1, gene expression, protein expression, recent-onset schizophrenia, treatment-resistant schizophrenia, biomarker 
analysis. 
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1. Introduction 
The selenium-binding protein 1 (SELENBP1) gene is located in chromosome 1q21.3 and encodes for a protein thought to be involved in 
mediating the effects of selenium in peripheral and central tissues (Bansal et al. , 1989, Glatt et al. , 2005, Yao et al. , 2008). SELENBP1 has 
also been implicated in ubiquitin-mediated protein degradation in a selenium-dependent manner (Jeong et al. , 2009). Post-mortem 
human brain studies have reported upregulation of SELENBP1 mRNA in the dorsolateral prefrontal cortex (DLPFC) of individuals with 
schizophrenia (Glatt, Everall, 2005, Kanazawa et al. , 2008, Udawela et al. , 2015). Similar evidence of upregulation of SELENBP1 mRNA in 
peripheral blood is also available in individuals with chronic schizophrenia (Glatt, Everall, 2005) and two single nucleotide 
polymorphisms in the  SELENBP1 gene (rs1078804 and rs2769264) have been identified as susceptible loci for  schizophrenia in a family-
wide association study (Kanazawa et al. , 2009). Although, findings in schizophrenia have been mixed as negative results are also 
available. Among those with recent onset schizophrenia, no difference in peripheral  mRNA expression was found relative to healthy 
controls (Yao, Schroder, 2008) and SELENBP1 protein levels in the DLPFC of individuals with schizophrenia also did not differ compared 
to controls (Udawela, Money, 2015). However, the overall evidence available to make firm conclusions about the association between 
SELENBP1 and schizophrenia, particularly specific sub-groups of schizophrenia is limited. Moreover, the effect of genetic mutations, 
lifestyle (smoking, alcohol use, substance abuse), and/or symptom severity on SELENBP1 mRNA and protein expression is yet to be 
investigated.  
The primary aim of this study was to measure peripheral SELENBP1 mRNA and protein levels in individuals with treatment-
resistant schizophrenia and those with recent onset schizophrenia and compare them to healthy controls. Aligned with our previous 
findings in post-mortem brain and peripheral blood of individuals with schizophrenia (Glatt, Everall, 2005), we hypothesized that 
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SELENBP1 mRNA and protein levels would be upregulated in schizophrenia relative to controls. Secondary aims of the study included 
exploration of whether expression levels are affected by variables such as age of illness onset, duration of illness, symptom severity, 
clozapine plasma level, and SELENBP1 genetic variation. 
2. Materials and Methods 
2.1 Participants 
The Structured Clinical Interview for DSM-IV Axis I Disorders (First et al. , 1997) or Mini International Neuropsychiatric Interview (MINI) 
(Sheehan et al. , 1998) were used to confirm diagnosis. Seventy-one schizophrenia patients were recruited from inpatient and outpatient 
clinics around Melbourne, Australia. All participants were aged between 18-65 years and were currently prescribed and taking clozapine. 
Per the current criteria, they were considered as ‘treatment-resistant’ as they failed to response to two or more previous trials of 
antipsychotics with persistent symptoms and poor functioning (Howes et al. , 2017). Thirty recent-onset schizophrenia patients (mean 
duration of illness < 1.5 years) were also recruited from clinical services in Melbourne as part of an ongoing neuroimaging study. A 
comparison group of fifty-seven healthy, unrelated controls was recruited from the general community and matched for age, gender and 
socio-economic status. Exclusion criteria for healthy controls included having a first-degree relative with psychiatric illness, neurological 
disease, current pregnancy/breast feeding, diabetes, head injury, seizures, prior or current use of antipsychotic medications, daily use of 
steroidal or nonsteroidal anti-inflammatory, immunosuppressive, corticoid or glucocorticoid drugs continuously for more than one week 
within the last month, generalized inflammatory condition/disease, premorbid IQ less than 70 with a documented history of 
developmental delay or intellectual disability,  thyroid dysfunction and substance abuse or dependence. In addition, recent onset 
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individuals were excluded if psychotic symptoms were entirely explained by drug use. Table 1 contains the details demographics of the 
participants. 
After an overnight fast, whole blood was collected and processed following the standard blood collection and processing protocol 
(see supplementary methods for more details). Participants were provided with written information and written consent was sought 
form all eligible individuals prior to participation. This study was approved by the Melbourne Health Human Research Ethics Committee 
(MHREC ID 2012.069 and 2012.066) and complied with the Declaration of Helsinki and its subsequent revisions (World Medical 
Association., 2013).  
2.2 Clinical measures 
To assess clinical symptoms, the Positive and Negative Syndrome Scale (PANSS) (Kay et al. , 1987) was used and the patients 
were scored according to the consensus five factor (positive, negative, disorganised, excitement, depression) PANSS model (Wallwork et 
al. , 2012) in the treatment-resistant schizophrenia (TRS) cohort. Data on Illicit drug use, tobacco, and alcohol consumption in the past 
three months was collected using a standard substance use questionnaire. In the recent onset schizophrenia patients, the Expanded Brief 
Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) was used to assess positive symptom severity. BPRS scores were converted 
to PANSS scores as previously described (Leucht et al. , 2013) to allow for consistent analysis of symptoms across cohorts. Current/last 
chlorpromazine equivalent dosage was calculated in all patients by following standard guidelines (American Psychiatric Association., 
1997, Woods, 2003) and among the treatment-resistant schizophrenia participants, clozapine plasma levels were measured.  
2.3 Selection of SNPs, DNA extraction and genotyping 
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Five haplotype tagging-single nucleotide polymorphisms (SNPs) which spanned the SELENBP1 gene were selected (rs10788804, 
rs2769264, rs2800953, rs2864118 and rs1752380) using the Northern and Western European ancestry (CEU) population as reference 
from the International Haplotype Map (HapMap) Project along with 60 unlinked ancestry informative markers representing the three 
HapMap phase III populations (Northern/Western European, Han Chinese, Yoruba in Nigeria) (Enoch et al. , 2006).  Supplementary Table 
S1 lists the SNPs and call rates. Two of these (rs1078804 and rs2769264) had been previously identified as being linked with 
schizophrenia (Kanazawa, Glatt, 2009). Genotyping was performed at the Australian Genome Research Facility (Brisbane, Australia) with 
the Sequenom MassARRAY MALDI-TOF genotyping system using Sequenom iPLEX Gold chemistries according to the manufacturer’s 
instructions (Sequenom, Inc., San Diego, CA). 
 
2.4 RNA extraction, cDNA synthesis and quantitative real-time PCR 
In the TRS cohort, total RNA extraction and quantification from whole blood was conducted using PureLink® RNA mini kit 
(ThermoFisher Scientific, Waltham, MA, USA) following standard manufacturer’s protocol. Total RNA was reverse transcribed to 
complementary DNA (cDNA) using SuperScript® IV First-Strand Synthesis System (Invitrogen, Foster city, CA, USA) using random 
hexamers. Complementary DNA (10.25ng) was used as a template for real-time PCR using master mix and gene specific validated Taqman 
assays from Applied Biosystems, Foster City, California, USA. Inventoried assays were used for SELENBP1 as well as the four reference 
genes (beta-actin, ACTB; ubiquitin C, UBC; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; and TATA box binding protein, TBP). See 
Supplementary Table S2 for a list of each of the probes and primers.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 MA
NU
SC
RIP
T
 
For gene expression measurement, 10.25 ng of cDNA was subjected to real-time PCR in duplicate using FAM-MGB TaqMan® 
gene expression probes (Invitrogen, Foster city, CA, USA) in 192x24 Dynamic Arrays IFC in Fluidigm® BioMark™ HD system (South San 
Francisco, CA, USA) at the Monash Health Translation Precinct Medical Genomics Facility (Hudson Institute of Medical Research, Clayton, 
VIC, Australia). In addition, no reverse transcriptase controls and no template controls were included to rule out genomic DNA 
contamination and reagent contamination, respectively. Adhering to minimum information for publication of RT-qPCR (MIQE) guidelines 
(Bustin et al. , 2009), normalized relative quantities (NRQ, i.e. 2-ΔCt where ΔCt= Ct(candidate gene) – Ct (geometric mean of reference genes))  of SELENBP1 
mRNA was calculated using the geometric mean expression of two reference genes (ACTB and UBC) that did not differ between groups. 
GAPDH and TBP were not used as reference genes because their expression differed significantly by group in the TRS cohort 
(Supplementary Figure S1). 
 
2.5 Protein quantification 
Human SELENBP1 ELISA kits (Catalogue number: abx153044) were obtained from Abbexa Ltd. (Cambridge, UK) and protein 
quantification in plasma was performed following the manufacturer’s protocol. Briefly, 100 µL of diluted plasma (1:4 dilution with 
0.01mol/L PBS; pH=7.0-7.2) from both cohorts and standards (0.156 ng/mL-10 ng/mL) were added to the wells in duplicate. The ELISA 
kits have a sensitivity of <0.054 ng/mL. Absorbance was measured on a SpectraMax® M3 multi-mode microplate reader (Molecular 
Devices, LLC; Sunnyvale, CA, USA) at 450nm wavelength. The standard curve (r2≥0.99) was generated by plotting relative absorbance of 
each standard solution on the Y-axis vs the respective concentration of the standard solution on the X-axis using a four-parameter logistic 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 MA
NU
SC
RIP
T
 
curve fit. The concentration of SELENBP1 protein in plasma samples was obtained by interpolating the absorbance values using the 
standard curve in GraphPad Prism 7. The final protein values were calculated after multiplying with the dilution factor (DF=4). 
2.6 Statistical Analysis 
Two-tailed tests were used for all statistical analyses. Quantile-quantile (Q-Q) plots and Shapiro-Wilk test were used to examine 
the normality of variable distributions. Independent sample t-tests were used to test differences for continuous variables between groups, 
while chi-squared tests (χ2) were used for categorical variables. To adjust for multiple comparisons, Benjamini-Hochberg step-up 
procedure (Benjamini and Hochberg, 1995) was used and effect size was calculated using the Hedges’ g method (Hedges and Olkin, 1985).  
2.7 SELENBP1 mRNA and protein analysis 
The normalized relative quantity for SELENBP1 mRNA transcript as well as SELENBP1 protein values were checked for 
normality using Q-Q plots (Supplementary Figure S2). In addition, we assessed the following variables as potential confounders: age, 
gender, RNA integrity number (for mRNA only), alcohol use, and smoking status. A variable was considered a confounder and included in 
our statistical models only when it was significantly different between groups (p<0.05) and was significantly associated with gene or 
protein expression. The normalised mRNA values were compared among groups (TRS cohort only) using generalized linear models based 
on their distribution and adjusted for appropriate covariates. Protein values were compared between all three groups (TRS, recent onset 
schizophrenia, and control) using the Kruskal-Wallis test.  The difference between groups were measured by post hoc pairwise 
comparison. Outliers were identified using the Grubbs’ test for outliers and removed from further analysis.  
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Spearman correlations were calculated between gene transcript/protein levels and symptom severity, age of illness onset, illness 
duration, current chlorpromazine equivalent dose, and clozapine plasma levels.  In the TRS cohort, mRNA transcript/protein levels 
between participants in positive symptom remission and non-remission were compared using a Mann-Whitney U test. Positive symptom 
remission was defined as a PANSS score of ≤3 on delusions, hallucinations, grandiosity and unusual thought content (Wallwork, Fortgang, 
2012). 
2.8 SNP/haplotype analysis 
The GRCh38/hg19 human genome reference assembly was used to map the SELENBP1 SNPs. Linkage disequilibrium (LD) 
between SNPs was examined in Haploview (Supplementary Figure S3)  and haplotype blocks determined using the solid spine method 
(Barrett et al. , 2005). For each individual, haplotypes were determined based on the best posterior probability procedure implemented in 
PLINK 1.07 (Purcell et al. , 2007). Generalised linear models were used to explore cis-regulatory effects of each SNP and haplotype on 
mRNA transcript and protein expression. Each model included genotype/haplotype, case status, genotype/haplotype x case status as well 
as other relevant covariates (age, gender, RIN, smoking, alcohol). Significant genotype/haplotype x case status interactions were analysed 
post hoc by case status stratification analyses.  
3. Results 
3.1 SELENBP1 mRNA and protein expression 
There was no difference for SELENBP1 mRNA level between individuals with treatment-resistant schizophrenia and healthy 
controls (praw= 0.234). However, Kruskal-Wallis test of SELENBP1 protein showed variance with diagnosis (H=11.756, df=2, p=0.003).  
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There was 15% lower level of plasma SELENBP1 protein in those with recent onset schizophrenia compared to healthy controls (praw = 
0.014; padj = 0.042) (Figure 1). We found no difference for plasma SELENBP1 protein level between TRS individuals and controls 
(praw=0.81) or between the TRS cohort and recent onset schizophrenia patients (praw = 0.171).  
3.2 SELENBP1 mRNA/protein expression and symptomatology 
We found a statistically significant positive correlation of plasma SELENBP1 protein level with duration of illness (Spearman’s 
rho = 0.292, padj = 0.028) and clozapine plasma level (Spearman’s rho = 0.253, padj = 0.036) in the treatment-resistant schizophrenia 
patients (Figure 2; Supplementary Table S3). There was no significant correlation for mRNA or protein level with symptom severity 
(Supplementary Table S4). Our exploratory analysis showed no difference for SELENBP1 mRNA and protein expression between 
individuals who had positive symptoms compared to those with non-remission (p=0.754 and 0.610 respectively).  
3.3 Genotype/haplotype effect on mRNA and protein expression 
We found trend level association for SNP rs2864118 (praw = 0.013; PB-H = 0.117) and haplotype block TCT (praw = 0.013; padj = 
0.117) with SELENBP1 protein expression in plasma in TRS patients. However, none of these associations survived correction for multiple 
comparisons (Supplementary Table S5). 
4. Discussion 
In the present study, we found no difference in peripheral SELENBP1 mRNA expression between individuals with treatment-resistant 
schizophrenia and healthy controls. However, we observed that plasma SELENBP1 protein level was lower in those individuals with 
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recent-onset schizophrenia. In the TRS individuals, SELENBP1 protein expression was confounded by clozapine plasma level and was 
positively correlated with duration of illness. Furthermore, we found none of the SNPs or haplotypes acted as expression quantitative trait 
loci (eQTL) for mRNA or protein expression.  
We did not find statistically significant difference for peripheral SELENBP1 mRNA expression between TRS patients and healthy 
controls. This findings does not support our hypothesis but is in agreement with a previous study that found similar outcome for this 
transcript in peripheral blood mononuclear cells in individuals experiencing their first hospitalisation with a schizophrenia spectrum 
disorder (schizophrenia, schizoaffective or schizophreniform disorder) (Yao, Schroder, 2008). Collectively, this suggests that peripheral 
mRNA expression pattern of SELENBP1 may not be dependent on disorder state.  Both studies investigated populations predominantly of 
Caucasian ancestry. Although one study reported an increased peripheral SELENBP1 mRNA expression in Han Chinese individuals with 
schizophrenia (Glatt, Everall, 2005), suggesting that ethnicity may play an important role for differential expression pattern of this 
transcript in schizophrenia. Several post-mortem human brain studies have demonstrated upregulation of SELENBP1 mRNA in the DLPFC 
in schizophrenia (Glatt, Everall, 2005, Kanazawa, Chana, 2008, Udawela, Money, 2015). Overall, this leads to the idea that there is tissue 
specific differential expression pattern for SELENBP1 mRNA in schizophrenia. Thus, the utility of using SELENBP1 mRNA as a peripheral 
biomarker in clinical settings needs to be validated in larger cohorts with populations from different ethnic backgrounds and disorder 
state. 
The novel finding of our study was of a lower level of plasma SELENBP1 protein in individuals with recent-onset schizophrenia. 
Although this findings does not support our a priori hypothesis, it is in line with previous studies that have shown selenium (Se) 
deficiency was associated with higher rates of schizophrenia (Jnr, 1994, Joyce, 1987) and lower plasma Se concentrations in patients with 
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schizophrenia (Arinola and Idonije, 2009, Vaddadi et al. , 2003). SELENBP1 binds selenium (Bansal et al. , 1990, Chang et al. , 1997), a 
trace element involved in neuroprotection (Dalla Puppa et al. , 2007, Porciuncula et al. , 2001, Yeo and Kang, 2007) but the primary 
function of SELENBP1 is yet to be identified as it is not a member of the selenoprotein family. The role of selenium and selenoproteins in 
brain are diverse, ranging from antioxidant and anti-inflammatory effects to phosphorylation of proteins and ion channels as well as brain 
cholesterol metabolism (Rayman, 2012, Solovyev, 2015). Two trace element studies showed no difference in plasma Se concentration 
between patients with schizophrenia and controls but SELENBP1 protein levels were not measured (Vidovic et al. , 2013, Yanik et al. , 
2004). SELENBP1 protein expression was also found to be lower in post-mortem liver from individuals with schizophrenia (Prabakaran et 
al. , 2007), thereby indicating that, lower peripheral protein expression of SELENBP1 may be a unique signature in schizophrenia. 
Moreover, we found that SELENBP1 protein expression was trend-level lower in those with treatment-resistant schizophrenia relative to 
healthy controls but is slightly higher in TRS compared to recent-onset schizophrenia, although neither was statistically significant. These 
findings support the dynamic nature of schizophrenia and suggest that SELENBP1 protein expression is dependent on disorder st ate by which 
transition into full blown symptoms may lead to reduced protein expression in plasma that later in the illness returns to or in some cases 
exceeds control levels. Longitudinal studies will be required to test this notion .  
Our finding of no difference in peripheral SELENBP1 protein expression between TRS and healthy controls supports a previous 
post-mortem human brain study that reported no difference for protein expression in the DLPFC in schizophrenia. A caveat of that study 
was that they did not include post-mortem human brain samples from recent-onset schizophrenia patients (Udawela, Money, 2015) and 
so we cannot confirm whether the same trajectory of lower SELENBP1 protein expression will be a characteristic feature in brain tissue in 
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early stage of schizophrenia. To the best of our knowledge, we are the first group to report decreased plasma SELENBP1 protein level in 
recent-onset schizophrenia and so it needs to be replicated and validated in other independent cohorts with larger sample size. 
Interestingly, our analyses showed that plasma SELENBP1 protein expression was positively correlated with clozapine plasma 
level in treatment-resistant patients. Clozapine is the medication of choice in TRS and may be responsible for causing upregulation of 
SELENBP1 protein in plasma. This hypothesis is supported by our finding of trend-level higher protein expression in TRS patients 
compared to recent-onset schizophrenia patients as none of the recent-onset schizophrenia patients were on clozapine. A previous study 
by Udawela et al. reported that animal models treated with chlorpromazine, thioridazine, and haloperidol had no effect on SELENBP1 
mRNA level in the CNS (Udawela, Money, 2015). Future studies should examine as to how clozapine causes changes in mRNA and protein 
expression in the CNS and periphery to clarify if changes in transcript and/or protein level are due to schizophrenia or is a drug effect. 
Furthermore, we found positive correlation of SELENBP1 protein expression with duration of illness in TRS patients, indicating that as the 
illness progresses the upregulation of protein becomes more evident. However, it is not clear whether this correlation represents a 
consequence of disease progression and/or a compensating effect to maintain normal cellular functions. Studies examining the pattern of 
SELENBP1 protein expression throughout the course of illness are required to verify the notion and discover the underlying mechanism. 
Our study had several limitations. First, we did not have mRNA measurements for SELENBP1 in recent-onset schizophrenia 
individuals and thus cannot confirm if lower SELENBP1 protein level was consequence of lower mRNA levels in recent-onset 
schizophrenia. Second, we did not have matched controls for recent-onset schizophrenia patients and we utilised a control group with a 
higher mean age group. Although, we adjusted for age in all our analysis we cannot completely rule out the possibility that older controls 
may have resulted in potential bias in the results. Third, we used whole blood for mRNA measurements and plasma for protein 
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measurement in the TRS cohort. It is not clear how our findings will relate to other accessible peripheral tissues (i.e. serum, lymphocytes, 
peripheral blood cells) commonly used in biomarker research. Furthermore, we were unable to determine what relationship, if any, 
peripheral levels of SELENBP1 have with brain levels as we did not have access to brain tissue from individuals with recent-onset 
schizophrenia. Fourth, our sample size was relatively small and our results should to be replicated and validated in independent cohorts. 
Fifth, we used populations predominantly of Caucasian ancestry and thus future investigation with population from other ethnic 
backgrounds are warranted. 
In summary, our results provide the first protein expression profile of plasma SELENBP1 in recent-onset schizophrenia as well as 
treatment-resistant schizophrenia. We observed a downregulation of plasma SELENBP1 protein among those with recent-onset 
schizophrenia. We further showed that increase in SELENBP1 protein expression in TRS may be regulated by clozapine plasma level as 
well as duration of illness suggesting that drug exposure and illness duration may have profound effect on protein expression. Further 
studies are required to verify if SELENBP1 can be used as a candidate biomarker for symptom remission and symptom severity in 
schizophrenia.  
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4.3 Highlights 
 Plasma SELENBP1 protein level was decreased in patients with recent-onset schizophrenia. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 MA
NU
SC
RIP
T
 
 No difference in peripheral SELENBP1 mRNA expression was detected between patients with treatment-resistant schizophrenia 
and healthy controls. 
 Peripheral SELENBP1 mRNA expression was positively correlated with clozapine plasma level and duration of illness in patients 
with treatment-resistant schizophrenia. 
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Figure 1: SELENBP1 mRNA and protein expression: (a) normalised relative quantities (NRQ) of SELENBP1 mRNA [treatment-resistant 
schizophrenia (TRS): 0.11, interquartile range (IQR)= 0.06-0.19; controls: 0.12, IQR: 0.06-0.21; Wald chi-square (χ2) =1.416, df=1, 
praw=0.234, Hedges’ g= 0.30)]; (b) plasma protein level of SELENBP1 [TRS: 1.84 ng/mL, IQR=1.33-2.41; recent onset schizophrenia: 1.74 
ng/mL, IQR=1.01-2.10; controls: 2.03 ng/mL, IQR=1.69-2.70; TRS vs recent-onset schizophrenia: Wald chi-square (χ2) =1.21, df=1, praw = 
0.171, g=0.51 ; TRS vs controls: Wald chi-square (χ2) =2.77, df=1, p=0.81, g=0.30; recent-onset schizophrenia vs controls: Wald chi-square 
(χ2) =6.16, df=1, praw=0.014, padj=0.042, g=0.90). Error bars represent median ± interquartile range. * p<0.05. 
Figure 2: The correlation of SELENBP1 protein with clinical factors in treatment-resistant schizophrenia patients: (a) correlation of 
SELENBP1 protein with clozapine plasma levels (Spearman’s rho = 0.253, padj = 0.036), (b) correlation of SELENBP1 protein with duration 
of illness (Spearman’s rho=0.292, padj = 0.028). 
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Table 1: Demographic data and clinical characteristics of participants 
Characteristic 
1. Treatment-
resistant 
schizophrenia 
(n=71) 
2. Recent 
onset 
schizophrenia 
(n=30) 
3. Controls 
(n=57) 
1 vs 2 1 vs 3 2 vs 3 
Age, mean (sd) years 40 (10) 21 (2) 40 (11) <0.001a 0.702a <0.001a 
Gender, n (%) males  53 (75) 23 (77) 35 (61) 1.000b 0.108b 0.231b 
RNA integrity number, mean (sd) 8.4 (0.9) - 8.7 (0.3) - 0.006a - 
Ancestry, n (%) CEU 62 (90) 23 (77) 50 (88) 0.189b 0.742b 0.165b 
Substance use in past three months, n (%)       
     Tobacco (smoked) 33 (47) 18 (60) 12 (21) 0.157b 0.003b <0.001b 
     Alcohol 59 (83) - 55 (97) - 0.016 b - 
     Cannabis 11 (15) - 7 (12) - 0.385 b - 
     Amphetamine 4 (6) - 2 (4) - 0.439 b - 
     Cocaine 0 (0) - 2 (4) - 0.137 b - 
     Opiates 1 (1) - 1 (2) - 0.990 b - 
Clozapine plasma level, mean (sd) µg/L 432 (234) - -  -  
Chlorpromazine equivalent (excluding 
clozapine) dosage mean (sd) mg/day 
142 (286) 338 (312) - 
- 
- 
- 
Age of onset, mean (sd) years 22.5 (6) 19.5 (2) -  - - 
Duration of illness, mean (sd) years 17 (8) 1.12 (1) -  - - 
PANSS scores, mean (sd)      - 
     Positive 10 (6) - -  - - 
     Negative 15 (5) - -  - - 
     Disorganized 8 (3) - -  - - 
     Excitement 6 (2) - -  - - 
     Depression 6 (3) - -  - - 
     Total 62 (14) 58 (16) -  - - 
RIN=RNA integrity number; PANSS=Positive and Negative Syndrome Scale; mg=milligram. 
aIndependent samples t-test , b Chi-square(χ2) test,  p<0.05 values are made bold 
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Fig: 1 
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Fig: 2 
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